Biotech Startups

Paques develops ANAMMOX®, a biological nitrogen removal system that converts ammonium and nitrite into nitrogen gas, serving municipal and industrial wastewater treatment facilities. The company's patented technology achieves significant operational cost savings and CO2 emission reductions compared to traditional nitrogen removal methods.

1 investor

Paques Biomaterials produces biodegradable PHA polymers from renewable resources and circular feedstocks using proprietary bacterial fermentation technology. The company operates demonstration and pilot facilities in the Netherlands to produce its branded Caleyda material for diverse industrial applications.

1 investor

1 investor

Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.

1 investor

Paralos is developing a modular M13 phage drug delivery platform that creates phage-drug conjugates to concentrate therapeutic payloads at specific targets. The platform pairs programmable target binding with payload presentation to localize drug exposure and engineer delivery around the therapeutic window.

1 investor

Pareon Biosystems has developed a multiplex biomarker quantification method that produces absolute measurements with built-in correction for non-specific binding. The approach uses low concentrations of common reagents and standard lab equipment such as PCR, targeting personalized/precision medicine applications in research and clinical settings, including resource-limited environments.

1 investor

Parhelia Bio builds laboratory instruments that automate sample preparation for spatial biology and flow cytometry, handling steps like dewaxing, antigen retrieval, staining, and panel mixing. It serves academic labs, core facilities, CROs, and biotech and pharma R&D teams, with an open REST API for integration and features supporting 21 CFR Part 11 compliance.

1 investor

Particella (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle technology to deliver nucleic acids to the intestinal epithelium. It focuses on oral mRNA medicines targeting the intestine.

1 investor

Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.

1 investor

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions. It works on therapies for patients living or born with CNS diseases and their families.

1 investor

PatenSee develops a contactless optical imaging system combined with AI that digitizes the 'look, listen, feel' examination of a patient's vascular access site to enable early prediction of stenosis and other complications. It serves dialysis clinics as a clinical support tool for monitoring hemodialysis patients' fistulas.

1 investor

Pathfinder Bio uses enzyme engineering and low-cost protein production to develop biocatalysts and biotechnological processes for molecular biology reagents, diagnostics, and industrial biomanufacturing. Its proprietary platform enables ultra-high throughput measurement of enzyme performance to design enzyme-based processes for sustainable chemical manufacturing.

1 investor

Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers. The company targets cancer immunotherapy applications across a broad range of solid tumors.

1 investor

Pathnostics is a CAP-accredited and CLIA-certified diagnostics laboratory offering histopathology, cytology, and molecular tests across urology, women's health, and gastroenterology. Its flagship platform, Guidance UTI, combines molecular detection with proprietary Pooled Antibiotic Susceptibility Testing (P-AST) for infectious disease and cancer diagnostics.

1 investor

iDose TR is a treatment for open-angle glaucoma and high eye pressure. The page serves as a patient story collection portal for individuals undergoing treatment.

1 investor

Pattern Computer is an AI and machine learning company that built a proprietary Pattern Discovery Engine (PDE) for finding novel patterns in high-dimensional, complex data, paired with explainable AI that makes model predictions human-readable. The company applies its system first to personalized medicine and medical research, with the broader aim of solving pressing health and scientific problems.

1 investor

Paulex Bio is developing an oral medicine aimed at regenerating beta cells to address the underlying cause of type 1 and type 2 diabetes. The company works in the biotech and therapeutics space with a goal of a functional cure for diabetes.

1 investor

PBD Biotech develops phage-based diagnostics, applying its technology to disease detection across clinical and veterinary applications. The company works in the diagnostics industry with expertise spanning disease management and policy.

1 investor

PBS Biotech develops Vertical-Wheel bioreactors and related accessories for scalable manufacturing of cell therapies, including allogeneic therapies derived from induced pluripotent stem cells, mesenchymal stem cells, and CAR-T or NK cells. It serves cell therapy developers from R&D through clinical trials and commercialization, offering products, consulting packages, and process scale-up support.

1 investor

PCI is a contract development and manufacturing organization (CDMO) that supports pharmaceutical clients from early-stage drug development through commercialization, including sterile drug manufacturing. It works across the product lifecycle to help bring therapies to market for patients worldwide.

1 investor

PCI Biotech develops bioprocessing technologies for manufacturing viral vectors and intracellular drug delivery solutions, serving immunotherapy and dermatology applications.

1 investor

PCI is a contract development and manufacturing organization (CDMO) that supports pharmaceutical and biotech clients from early-stage development through commercialization, including sterile drug manufacturing. It operates globally to help bring therapies to market across the product lifecycle.

1 investor

Pearl Bio develops technologies for genome engineering, ribosome engineering, and biomanufacturing to enable production of novel proteins, chemicals, and materials for biotechnology and medicine.

1 investor

PECA Labs develops cardiovascular implants—including vascular grafts and the MASA Valve, a polymeric bi-leaflet valved conduit for pulmonary valve reconstruction—based on a proprietary tunable polymeric material platform. Its devices target both pediatric and adult patients, with the MASA Valve currently under investigational use in a U.S. clinical trial.

1 investor